KorrekturOpen access
Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”
Obesity · 2026-06 · 34 (6) · 1354-1354
DOI: 10.1002/oby.70194 ↗At a glance
Korrektur in Obesity, published online on 2026-03-22. The full text is freely available in PubMed Central.
Abstract (original language)
Ebda abstract disponibbli.
Cite
APA
(2026). Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”. Obesity, 34(6), 1354-1354. https://doi.org/10.1002/oby.70194
Vancouver
Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”. Obesity. 2026;34(6):1354-1354. doi:10.1002/oby.70194
BibTeX
@article{euvimed2026,
title = {Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”},
journal = {Obesity},
year = {2026},
volume = {34},
number = {6},
pages = {1354--1354},
doi = {10.1002/oby.70194}
}
EUVIMED